In vivo CRISPR knockdown remains stable at 24 months in humans
A one-off infusion edited a gene inside patients' livers, and two years later the effect is still holding. Nothing worrying has shown up in that time. This matters for longevity because any future preventive gene therapy needs exactly this kind of long, boring safety record.
What happened
A two-year open-label extension reported sustained target-protein knockdown in participants who received a single in vivo CRISPR infusion (n = 62 followed to 24 months).
No new safety signal was identified over the additional follow-up period, and the primary durability endpoint was met.
The measured outcome is a protein biomarker, so these results do not by themselves establish broader clinical or longevity benefit.
Why it matters
Durability is the entire economic argument for in vivo editing: a single administration replacing lifelong therapy.
For aging biology, the relevant read-through is delivery. Lipid nanoparticle delivery to the liver is now well characterised, which lowers risk for any longevity target expressed there.
Regulators gain a longer safety dataset, which shapes how tolerant they may be of preventive rather than curative indications.
Current LONGEFI Signal
LONGEFI's deterministic scientific synthesis — not a market view.
How strong the underlying evidence is.
How new or meaningfully different the finding is.
How close the evidence is to meaningful human application.
How likely this is to matter commercially or strategically.
LONGEFI Signal is a 0–100 comparison score across scientific evidence, novelty, human relevance and market relevance. It is not an investment rating and not a prediction of investment performance.LONGEFI Signal is a 0–100 comparison score built from four analytical dimensions — scientific evidence, novelty, human relevance and market relevance — so developments can be ranked against each other. NOT AN INVESTMENT RATING: it is not a prediction of investment performance and not a view on any security.
Science explained
The terminology, in plain language.
- In vivo editing
- Editing genes inside the body, rather than removing cells, editing them in a lab and putting them back.
- Lipid nanoparticle
- A tiny fat bubble that carries the editing instructions into cells, mostly liver cells.
- Knockdown
- Reducing how much of a particular protein the body makes.
- Durability
- Whether a one-time treatment keeps working years later.
What would change our view?
The findings that would raise or lower this Signal.
Larger controlled trial
Durability confirmed in a randomised Phase 3 population.
Second target organ
Equivalent stability demonstrated outside the liver.
Off-target findings
Long-term sequencing revealing unintended edits in treated patients.
Knockdown drift
Protein levels recovering toward baseline in later follow-up.
Sources & traceability
Supporting documents, underlying datasets and independent sources are not the same thing.
- Extension study
NEJM
- Original Phase 1
NEJM
Everything below is commercial interpretation. It does not form part of the LONGEFI Scientific Signal.
Companies & assets
Exposure to the technology discussed, not an investment view.
This development may be relevant to this company’s longevity programs.
In vivo CRISPR gene editing
Durable in vivo editing turns chronic disease management into single-administration treatment — the delivery template later longevity interventions will need.
This development may be relevant to this company’s longevity programs.
Base editing
Lower-risk editing chemistry broadens the set of diseases — and eventually risk genes — that can be safely addressed.
Market implications
Which parts of the field this touches, and over what horizon.
Intellia Therapeutics
Potential beneficiaryIn vivo CRISPR knockdown delivered to the liver.
Durability at 24 months lowers platform risk across the company's pipeline, not only the lead programme.
Beam Therapeutics
Technology validationBase editing using comparable delivery chemistry.
Supports the shared premise that a single systemic dose can produce years-long protein knockdown.
- In vivo CRISPR
- Base editing
- LNP delivery
- Genetic medicine
- Delivery technology
- Rare disease
- Cardiometabolic
Near-term relevance for genetic medicine broadly. For longevity specifically the implication is infrastructural: durable, well-tolerated delivery is a precondition for any preventive genetic intervention.
LONGEFI does not issue buy, sell or hold recommendations, and nothing here is personalized financial advice.
Trend connections
How this connects to themes LONGEFI tracks over time.
This is the first development LONGEFI has logged in this theme.